Lilly Sees Positive Results With Next-Gen Alzheimer’s Drug Donanemab

Patients Saw Less Cognitive, Functional Decline In Phase II Trial

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.